Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences
DUBLIN, Sept. 2, 2026 /PRNewswire/ — Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that company management will participate in fireside chats at the following investor conferences:
- Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026, at 1:30 p.m. ET
- Citi 2026 Biopharma Back to School Summit on Thursday, September 10, 2026, at 10:40 a.m. ET
- Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026, at 12:20 p.m. ET
- Deutsche Bank Healthcare Summit on Wednesday, September 16, 2026, at 8:00 a.m. ET
Audio webcasts of the fireside chats will be available via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations. A replay of the webcasts will be archived on the website for 30 days.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with rare disease — often with limited or no therapeutic options. We have a diverse portfolio of medicines, including leading therapies addressing epilepsies, cancers and sleep disorders. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visit www.jazzpharmaceuticals.com for more information.
Contacts
Investors:
[email protected]
Ireland +353 1 634 7800
U.S. +1 650 496 2717
Media:
[email protected]
Ireland +353 1 637 2141
U.S. +1 215 867 4948

View original content to download multimedia:https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-to-participate-in-upcoming-investor-conferences-302868145.html
SOURCE Jazz Pharmaceuticals plc

More from Cision PR Newswire
See all
Legacy Healthcare Welcomes U.S. Congressional Legislation Proposing 12-Year Market Exclusivity for US FDA Newly Approved Botanical Drugs

Triskell Software Positioned for the First Time in the 2026 Gartner® Magic Quadrant™ for Adaptive Project Management and Reporting

RAMINVEST HOLDING DIFC Unveils an Integrated Ecosystem for Commodity Trade with Africa

Qapture Investments Establishes Investment Manager and Acquires Hermetik Trading’s DeFi Strategies; Appoints Brendan MacNeil as Head of DeFi
Recommended for you
More stories
Future of AICysic CEO Says Paying for an AI Model Doesn’t Prove Your Host Ran It
AI & TechnologyFrom self-driving excavators to AI leasing agents, proptech’s AI moment has arrived
AI & TechnologyAI literacy shouldn’t begin in the workplace. It should begin in primary school.
DataThe Data Centre Is Becoming a Product
AI & TechnologyToo often, AI narrows rather than widens access. Here’s how the tech industry can fix it
AI & Technology